Treating Parents With ADHD and Their Young Children Via Telehealth: A Hybrid Type I Effectiveness-Implementation Trial (TPAC)
2/2 Treating Mothers With ADHD and Their Young Children Via Telehealth: A Hybrid Type I Effectiveness-Implementation Trial
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 3
Contacts and Locations
Study Contact
Study Contact
- Name: Andrea M Chronis-Tuscano, Ph.D.
- Phone Number: 301-405-9640
- Email: achronis@umd.edu
Study Locations
-
-
Maryland
-
College Park, Maryland, United States, 20742
- University of Maryland
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Child Inclusion Criteria:
- Be at least 3 years old and no more than 8 years old
- ADHD medication naive or have not had an adequate trial of stimulant medications
- Have ≥5 inactivity or ≥5 hyperactivity symptoms rated as 1 or 2 on the Vanderbilt
- Have a CGI-S-ADHD rating ≥4 and <7
Child Exclusion Criteria:
- Severe ADHD (CGI-S-ADHD score of greater than 6)
Parent Inclusion Criteria:
- Be at least 21 years old and English-speaking
- Meet full DSM-5 criteria for ADHD (any subtype)
- Have findings on physical examination, laboratory studies, vital signs, and electrocardiogram judged to be normal for age with no contraindications for stimulant medication
- Have pulse and blood pressure (BP) within 95% of age and gender mean
- Women of childbearing potential agree to use a medically accepted contraception method consistently
- Parents with common comorbid conditions will be included provided that: (a) they do not report active suicidal ideation with intent (i.e. Beck Depression Inventory (BDI)-II score of 2 or 3 to Q9 which assesses suicidal thoughts); and (b) if receiving an antidepressant medication, their medication is well-tolerated, has not changed within 30 days, and the prescribing physician approves of their participation in the study
- Must have regular access to a computer or phone that can be used to deliver the behavioral parent training
Parent Exclusion Criteria:
- History of allergic or other severe negative reactions to study medications
- Substance abuse in the past 3 months, or a positive baseline urinary toxic screen that is not explained by a time-limited medical circumstance
- Current bipolar disorder, schizophrenia, psychoses, or other primary psychiatric disorder requiring other immediate treatment
- History of chronic/acute medical disorder for which stimulant therapy would be contraindicated (e.g., glaucoma, hypertension)
- Stimulant medication for ADHD in the past 30 days
- Is pregnant
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Parent Stimulant Medication + Child Treatment Strategy
Parent stimulant medication first followed by a child treatment strategy consisting of behavioral parent training followed by a recommendation for child stimulant medication to the primary care provider if the child remains impaired.
|
Parents will receive 10 sessions of behavioral parent training with components specifically targeted toward parents with ADHD.
Treatment will be delivered via telehealth.
The MAS protocol will include a 2-4 -week open-label titration beginning at 20 mg and dose level will be increased weekly at telehealth visits with the psychopharmacologist until an optimal response or maximum dose of 60 mg.
|
|
Active Comparator: Child Treatment Strategy
Child treatment strategy consisting of behavioral parent training followed by a recommendation for child stimulant medication to the primary care provider if the child remains impaired.
In this arm, parents do not receive stimulant medication before behavioral parent training.
|
Parents will receive 10 sessions of behavioral parent training with components specifically targeted toward parents with ADHD.
Treatment will be delivered via telehealth.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in Child Impairment
Time Frame: Up to 16 weeks post-randomization
|
Assessed using the Clinical Global Impressions (CGI) - Severity scale.
Minimum value = 1, maximum value = 7.
Higher scores indicate worse outcomes.
The Child CGI outcome was collected for enrolled parent-child dyads.
Community stakeholders and providers were not assessed for this outcome.
|
Up to 16 weeks post-randomization
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Andrea Chronis-Tuscano, Ph.D., University of Maryland, College Park
Publications and helpful links
General Publications
- Curran GM, Bauer M, Mittman B, Pyne JM, Stetler C. Effectiveness-implementation hybrid designs: combining elements of clinical effectiveness and implementation research to enhance public health impact. Med Care. 2012 Mar;50(3):217-26. doi: 10.1097/MLR.0b013e3182408812.
- Chronis-Tuscano A, O'Brien KA, Johnston C, Jones HA, Clarke TL, Raggi VL, Rooney ME, Diaz Y, Pian J, Seymour KE. The relation between maternal ADHD symptoms & improvement in child behavior following brief behavioral parent training is mediated by change in negative parenting. J Abnorm Child Psychol. 2011 Oct;39(7):1047-57. doi: 10.1007/s10802-011-9518-2.
- Chronis-Tuscano A, Seymour KE, Stein MA, Jones HA, Jiles CD, Rooney ME, Conlon CJ, Efron LA, Wagner SA, Pian J, Robb AS. Efficacy of osmotic-release oral system (OROS) methylphenidate for mothers with attention-deficit/hyperactivity disorder (ADHD): preliminary report of effects on ADHD symptoms and parenting. J Clin Psychiatry. 2008 Dec;69(12):1938-47. doi: 10.4088/jcp.v69n1213. Epub 2008 Dec 2.
- Schoenfelder EN, Chronis-Tuscano A, Strickland J, Almirall D, Stein MA. Piloting a Sequential, Multiple Assignment, Randomized Trial for Mothers with Attention-Deficit/Hyperactivity Disorder and Their At-Risk Young Children. J Child Adolesc Psychopharmacol. 2019 May;29(4):256-267. doi: 10.1089/cap.2018.0136. Epub 2019 Apr 13.
- Chronis-Tuscano A, Rooney M, Seymour KE, Lavin HJ, Pian J, Robb A, Efron L, Conlon C, Stein MA. Effects of maternal stimulant medication on observed parenting in mother-child dyads with attention-deficit/hyperactivity disorder. J Clin Child Adolesc Psychol. 2010;39(4):581-7. doi: 10.1080/15374416.2010.486326.
- Chronis-Tuscano A, Wang CH, Woods KE, Strickland J, Stein MA. Parent ADHD and Evidence-Based Treatment for Their Children: Review and Directions for Future Research. J Abnorm Child Psychol. 2017 Apr;45(3):501-517. doi: 10.1007/s10802-016-0238-5.
- Chronis-Tuscano A, Bounoua N, Danko CM, Almirall D, Lui JHL, Marschall D, Taubin D, Bui HNT, Marsh NP, Efron L, Dorfman J, Lorenzo NE, Dvorsky M, Bennett IM, Atabaki SM, Robb AS. Treating parents with ADHD and their children (TPAC): a hybrid effectiveness-implementation, randomized controlled trial. J Child Psychol Psychiatry. 2026 Aug 18. doi: 10.1111/jcpp.70222. Online ahead of print.
- Lui JHL, Danko CM, Triece T, Bennett IM, Marschall D, Lorenzo NE, Stein MA, Chronis-Tuscano A. Screening for parent and child ADHD in urban pediatric primary care: pilot implementation and stakeholder perspectives. BMC Pediatr. 2023 Jul 13;23(1):354. doi: 10.1186/s12887-023-04082-2.
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Mental Disorders
- Neurodevelopmental Disorders
- Attention Deficit and Disruptive Behavior Disorders
- Attention Deficit Disorder with Hyperactivity
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Autonomic Agents
- Peripheral Nervous System Agents
- Neurotransmitter Agents
- Membrane Transport Modulators
- Adrenergic Agents
- Central Nervous System Stimulants
- Dopamine Uptake Inhibitors
- Neurotransmitter Uptake Inhibitors
- Dopamine Agents
- Adrenergic Uptake Inhibitors
- Sympathomimetics
- Amphetamine
Other Study ID Numbers
Other Study ID Numbers
- 1R01MH118320 (U.S. NIH Grant/Contract)
- 1R01MH118313 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.